References of "PIERARD, Luc"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPlace du traitement médical bradycardisant dans l’insuffisance cardiaque
tridetti, j; KRZESINSKI, François ULg; D'ORIO, Virginie ULg et al

in Revue Médicale de Liège (2017), 72

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailMaladie coronaire et pratique sportive
ANCION, Arnaud ULg; KAUX, Jean-François ULg; PIERARD, Luc ULg et al

in Revue Médicale de Liège (2017), 72(6), 281-287

Detailed reference viewed: 27 (1 ULg)
Full Text
Peer Reviewed
See detailProtection cardiovasculaire et rénale du patient diabétique de type 2 : le point après EMPA-REG OUTCOME et LEADER
SCHEEN, André ULg; PIERARD, Luc ULg; KRZESINSKI, Jean-Marie ULg et al

in Revue Médicale de Liège (2016), 71(09), 376-381

Summary : Type 2 diabetes (T2D), often associated with arterial hypertension, represents a high risk of cardiovascular disease and nephropathy. Two clinical trials demonstrate the superiority versus a ... [more ▼]

Summary : Type 2 diabetes (T2D), often associated with arterial hypertension, represents a high risk of cardiovascular disease and nephropathy. Two clinical trials demonstrate the superiority versus a placebo of two antidiabetic drugs in patients with T2D and high cardiovascular risk : empagliflozin, an inhibitor of sodium-glucose type 2 (SGLT2) cotransporters, in EMPA-REG OUTCOME and liraglutide, an agonist of glucagon-like peptide-1 (GLP-1) receptors, in LEADER. Both medications showed a significant reduction in major cardiovascular events (-14 and -13 %, respectively), cardiovascular mortality (-38 and -22%), all-cause mortality (-32 and -15 %) and renal events (-39 et -22 %). The underlying protective mechanisms remain controverted. Ongoing studies should allow to decide whether the benefits are specific to each molecule or may be attributed to a class effect. [less ▲]

Detailed reference viewed: 62 (4 ULg)
Peer Reviewed
See detailHeart Team Liege - Session Video Link
PIERARD, Luc ULg; vahanian, Alec; LANCELLOTTI, Patrizio ULg et al

Conference (2016, September)

Detailed reference viewed: 99 (3 ULg)
Peer Reviewed
See detailHeart Team Session
PIERARD, Luc ULg; LANCELLOTTI, Patrizio ULg; PETERMANS, Jean ULg et al

Conference (2016, August)

Detailed reference viewed: 30 (3 ULg)
Full Text
Peer Reviewed
See detailComment je traite... la sténose aortique asymptomatique
MEURICE, Caroline ULg; DULGHERU, Raluca Elena ULg; PIERARD, Luc ULg

in Revue Médicale de Liège (2016), (71), 6-10

Detailed reference viewed: 61 (15 ULg)
Full Text
Peer Reviewed
See detailRecommandations européennes sur la prise en charge de l’endocardite infectieuse (partim 1)
IOVINO, Alessandra ULg; MARCHETTA, Stella ULg; DULGHERU, Raluca Elena ULg et al

in Revue Médicale de Liège (2016), 71(6), 281-286

Detailed reference viewed: 11 (1 ULg)
Peer Reviewed
See detailHeart valve disease: (aorte valve disease): aortic regurgitation
TRIBOUILLOY, C; LANCELLOTTI, Patrizio ULg; PETERS, F. et al

in THE EACVI TEXTBOOK OF ECHOCARDIOGRAPHY - SECOND EDITION (2016)

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailLeft ventricular regional function and maximal exercise capacity in aortic stenosis.
DULGHERU, Raluca Elena ULg; Magne, Julien; DAVIN, Laurent ULg et al

in European Heart Journal - Cardiovascular Imaging (2016)

AIMS: The objective assessment of maximal exercise capacity (MEC) using peak oxygen consumption (VO2) measurement may be helpful in the management of asymptomatic aortic stenosis (AS) patients. However ... [more ▼]

AIMS: The objective assessment of maximal exercise capacity (MEC) using peak oxygen consumption (VO2) measurement may be helpful in the management of asymptomatic aortic stenosis (AS) patients. However, the relationship between left ventricular (LV) function and MEC has been relatively unexplored. We aimed to identify which echocardiographic parameters of LV systolic function can predict MEC in asymptomatic AS. METHODS AND RESULTS: Asymptomatic patients with moderate to severe AS (n = 44, aortic valve area <1.5 cm2, 66 +/- 13 years, 75% of men) and preserved LV ejection fraction (LVEF > 50%) were prospectively referred for resting echocardiography and cardiopulmonary exercise test. LV longitudinal strain (LS) of each myocardial segment was measured by speckle tracking echocardiography (STE) from the apical (aLS) 4-, 2-, and 3-chamber views. An average value of the LS of the analysable segments was provided for each myocardial region: basal (bLS), mid (mLS), and aLS. LV circumferential and radial strains were measured from short-axis views. Peak VO2 was 20.1 +/- 5.8 mL/kg/min (median 20.7 mL/kg/min; range 7.2-32.3 mL/kg/min). According to the median of peak VO2, patients with reduced MEC were significantly older (P < 0.001) and more frequently females (P = 0.05). There were significant correlations between peak VO2 and age (r = -0.44), LV end-diastolic volume (r = 0.35), LV stroke volume (r = 0.37), indexed stroke volume (r = 0.32), and E/e' ratio (r = -0.37, all P < 0.04). Parameters of AS severity and LVEF did not correlate with peak VO2 (P = NS for all). Among LV deformation parameters, bLS and mLS were significantly associated with peakVO2 (r = 0.43, P = 0.005, and r = 0.32, P = 0.04, respectively). With multivariable analysis, female gender (beta = 4.9; P = 0.008) and bLS (beta = 0.50; P = 0.03) were the only independent determinants (r2 = 0.423) of peak VO2. CONCLUSION: In asymptomatic AS, impaired LV myocardial longitudinal function determines reduced MEC. Basal LS was the only parameter of LV regional function independently associated with MEC. [less ▲]

Detailed reference viewed: 106 (23 ULg)
Full Text
Peer Reviewed
See detailApport du cathétérisme cardiaque dans le diagnostic et le traitement de la maladie coronarienne avant 40 ans
MEURICE, Caroline; LEGRAND, Victor ULg; PIERARD, Luc ULg

in Revue Médicale de Liège (2016), 71(3), 129-136

Detailed reference viewed: 51 (9 ULg)
Full Text
Peer Reviewed
See detailImpact of Serial B-Type Natriuretic Peptide Changes for Predicting Outcome in Asymptomatic Patients With Aortic Stenosis.
Henri, Christine; DULGHERU, Raluca Elena ULg; Magne, Julien et al

in The Canadian journal of cardiology (2016)

BACKGROUND: The aim of this study was to determine the impact on the outcome of serial B-type natriuretic peptide (BNP) changes during follow-up in asymptomatic patients with >/= moderate aortic stenosis ... [more ▼]

BACKGROUND: The aim of this study was to determine the impact on the outcome of serial B-type natriuretic peptide (BNP) changes during follow-up in asymptomatic patients with >/= moderate aortic stenosis (AS) and preserved left ventricular ejection fraction. METHODS: We prospectively screened 69 patients who underwent comprehensive transthoracic echocardiography, BNP level measurement at baseline and after every 6 or 12 months. Annualized BNP changes were calculated as the difference between the last and baseline BNP measurements divided by the duration of follow-up. The primary endpoint was the occurrence of symptoms, aortic valve replacement, or cardiovascular death. RESULTS: During a follow-up of 30 +/- 19 months, 43 patients experienced a cardiac event. These patients were significantly older (73 +/- 9 vs 65 +/- 16 years; P = 0.010), had more often dyslipidemia (79% vs 42%; P = 0.038), more severe AS (peak velocity: 3.9 +/- 0.6 vs 3.5 +/- 0.6 m/s; P = 0.002), larger indexed left atrial area (10.2 +/- 2.5 vs 8.7 +/- 1.9 cm2/m2; P = 0.006), and a higher increase in annualized BNP (+90 +/- 155 vs +7 +/- 49 pg/mL/y; P = 0.010). Patients with higher annualized BNP changes (> 20 pg/mL/y) had a significantly lower cardiac event-free survival (1 year: 63 +/- 8% vs 97 +/- 3%; 3 years: 31 +/- 8% vs 68 +/- 8%; P < 0.001). Using the multivariate Cox proportional hazards model, higher annualized BNP changes were significantly associated with increased risk of cardiac events (hazard ratio: 2.73, 95% confidence interval: 1.27-5.86; P = 0.010) after adjustment for age, dyslipidemia, and echocardiographic parameters. CONCLUSIONS: In asymptomatic patients with AS and preserved left ventricular ejection fraction, the use of serial BNP changes may help to anticipate development of class I indication for aortic valve replacement. [less ▲]

Detailed reference viewed: 62 (8 ULg)
Full Text
Peer Reviewed
See detailSTENOSE AORTIQUE SEVERE ASYMPTOMATIQUE A FRACTION D'EJECTION VENTRICULAIRE GAUCHE PRESERVEE. EVALUATION A L'EFFORT: QUELS RESULTATS ET QUELLES DECISIONS?
BENSAHI, I; ELFHAL, A; MAGNE, Julien et al

in Annales de Cardiologie et d'Angeiologie (2015), 64(2), 100-108

Detailed reference viewed: 42 (5 ULg)
Full Text
Peer Reviewed
See detailRAC avec discordance gradient/surface
HENRI, Christine; PIERARD, Luc ULg

in Réalités Cardiologiques (2015), 307

Detailed reference viewed: 30 (0 ULg)
Full Text
Peer Reviewed
See detailExercice stress echocardiography in secondary mitral regurgitation : impact of pulmonary hypertension
MAGNE, Julien; PIERARD, Luc ULg; LANCELLOTTI, Patrizio ULg

in Archives of Cardiovascular Diseases (2015, January), 7

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailElevated Plasma Soluble ST2 Is Associated with Heart Failure Symptoms and Outcome in Aortic Stenosis.
LANCELLOTTI, Patrizio ULg; DULGHERU, Raluca Elena ULg; Magne, Julien et al

in PloS one (2015), 10(9), 0138940

B-type natriuretic peptide (BNP) is often used as a complementary finding in the diagnostic work-up of patients with aortic stenosis (AS). Whether soluble ST2, a new biomarker of cardiac stretch, is ... [more ▼]

B-type natriuretic peptide (BNP) is often used as a complementary finding in the diagnostic work-up of patients with aortic stenosis (AS). Whether soluble ST2, a new biomarker of cardiac stretch, is associated with symptomatic status and outcome in asymptomatic AS is unknown. sST2 and BNP levels were measured in 86 patients (74+/-13 years; 59 asymptomatic, 69%) with AS (<1.5 cm2) and preserved left ventricular ejection fraction who were followed-up for 26+/-16 months. Both BNP and sST2 were associated with NYHA class but sST2 (>23 ng/mL, AUC = 0.68, p<0.01) was more accurate to identify asymptomatic patients or those who developed symptoms during follow-up. sST2 was independently related to left atrial index (p<0.0001) and aortic valve area (p = 0.004; model R2 = 0.32). A modest correlation was found with BNP (r = 0.4, p<0.01). During follow-up, 29 asymptomatic patients (34%) developed heart failure symptoms. With multivariable analysis, peak aortic jet velocity (HR = 2.7, p = 0.007) and sST2 level (HR = 1.04, p = 0.03) were independent predictors of cardiovascular events. In AS, sST2 levels could provide complementary information regarding symptomatic status, new onset heart failure symptoms and outcome. It might become a promising biomarker in these patients. [less ▲]

Detailed reference viewed: 45 (11 ULg)
Full Text
Peer Reviewed
See detailNew biomarkers for primary mitral regurgitation.
Deroyer, Céline ULg; Magne, Julien; Moonen, Marie ULg et al

in Clinical proteomics (2015), 12

BACKGROUND: Mitral regurgitation is a frequent valvular heart disease affecting around 2.5 % of the population with prevalence directly related to aging. Degeneration of mitral valve is broadly considered ... [more ▼]

BACKGROUND: Mitral regurgitation is a frequent valvular heart disease affecting around 2.5 % of the population with prevalence directly related to aging. Degeneration of mitral valve is broadly considered as a passive ongoing pathophysiological process and little is known about its physiological deregulation. The purpose of this study was to highlight new biomarkers of mitral regurgitation in order to decipher the underlying pathological mechanism as well as to allow the diagnosis and the monitoring of the disease. RESULTS: Modulation of various blood proteins expression was examined in patients suffering from different grades of mitral regurgitation (mild, moderate and severe) compared to healthy controls. To this end, several routine clinical assays and the multi analyte profile technology targeting 184 proteins were used. High-density lipoprotein, apolipoprotein-A1, haptoglobin and haptoglobin-alpha2 chain levels significantly decreased proportionally to the degree of mitral regurgitation when compared to controls. High-density lipoprotein and apolipoprotein-A1 levels were associated with effective regurgitant orifice area and regurgitant volume. Apolipoprotein-A1 was an independent predictor of severe mitral regurgitation. Moreover, with ordinal logistic regression, apolipoprotein-A1 remained the only independent factor associated with mitral regurgitation. In addition, myxomatous mitral valves were studied by immunocytochemistry. We observed an increase of LC3, the marker of autophagy, in myxomatous mitral valves compared with healthy mitral valves. CONCLUSION: These potential biomarkers of mitral regurgitation highlighted different cellular processes that could be modified in myxomatous degenerescence: reverse cholesterol transport, antioxidant properties and autophagy. [less ▲]

Detailed reference viewed: 93 (19 ULg)
Full Text
Peer Reviewed
See detailCardiovascular outcome in systemic sclerosis.
Voilliot, Damien; Magne, Julien; DULGHERU, Raluca Elena ULg et al

in Acta cardiologica (2015), 70(5), 554-63

OBJECTIVES: Cardiovascular involvement is recognized as a poor prognostic factor in systemic sclerosis (SSc). The aim of this study was to evaluate the usefulness of nailfold video-capillaroscopy (NVC ... [more ▼]

OBJECTIVES: Cardiovascular involvement is recognized as a poor prognostic factor in systemic sclerosis (SSc). The aim of this study was to evaluate the usefulness of nailfold video-capillaroscopy (NVC), brain natriuretic peptide (BNP) blood level and exercise echocardiography to predict the occurrence of cardiovascular events in SSc. METHODS: We prospectively enrolled 65 patients with SSc (age 54+/-14 years, 30% female) followed in CHU Sart-Tilman, Liege, Belgium. All patients underwent graded semi-supine exercise echocardiography. Both baseline resting pulmonary hypertension (PH) and PH during follow-up (FUPH) were defined as systolic pulmonary arterial pressure (sPAP)>35 mmHg, and exercise-induced PH (EIPH) as sPAP>50 mmHg during exercise. RESULTS: EIPH was present in 21 patients. During FU (27+/-18 months), 13 patients developed FUPH and 9 presented cardiovascular complications. Patients with cardiovascular events were significantly older (63+/-14 vs 52+/-13 years; P=0.03), presented more frequently NVC grade>2 (89 vs 43%; P=0.009), had higher resting and exercise sPAP (30+/-6 vs 24+/-6; P=0.007 and 57+/-13 vs 44+/-13 vs mmHg; P=0.01, respectively), and higher BNP blood level (112+/-106 vs 26+/-19 pg/ml; P=0.0001). After adjustment for age and gender, NVC grade>2 (ss=2.4+/-1.1; P=0.03), EIPH (ss=2.30+/-1.13; P=0.04), FUPH (ss=0.24+/-0.09; P=0.01 and ss=3.52+/-1.16; P=0.002, respectively;) and BNP (ss=0.08+/-0.04; P=0.02) were independent predictors of CV events. Beyond age, an incremental value of EIPH, BNP and NVC grade>2 was predictive of cardiovascular events (P<0.001). CONCLUSION: Cardiovascular complications are not rare in SSc (18%). NVC, BNP blood level assessment and exercise echocardiography could be useful tools to identify patients at risk of SSc. [less ▲]

Detailed reference viewed: 42 (3 ULg)